QT Imaging Holdings Inc (QTI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.64-4.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · QTI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue scaling commercial adoption and shipments to meet full-year 2026 revenue guidance of about $39 million.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $3.7 million in 2025-Q2 to $7.4 million in 2026-Q2 (+100%), with first half 2026 revenue at $14.0 million, a 116% increase over first half 2025. Management reaffirmed full-year 2026 revenue guidance of approximately $39 million each quarter, showing delivery on commercial scaling and growth trajectory.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Reaffirms full-year 2026 revenue guidance of approximately $39 million.”
“The Company reaffirms guidance for 2026 revenue to be approximately $39 million.”
“Looking ahead, we expect revenue in 2026 to be approximately $39 million.”
Build scalable U.S. commercial organization with direct sales and distribution partnerships to accelerate adoption and installed base growth.
Stated as a priority in 2 of last 3 quarters. Management expanded the direct U.S. commercial team with new regional sales leaders in 2026-Q1 and emphasized this expansion again in 2026-Q2. This supports the growing commercial execution evidenced by revenue growth and increased scanner shipments, indicating progress in building scalable commercial capabilities.
“Expanded direct U.S. commercial capabilities to accelerate adoption.”
“Expanded our direct U.S. commercial organization with appointments of two experienced regional sales leaders.”
Obtain regulatory clearances and authorizations in key international markets to support commercial expansion.
Stated as a priority in 2 of last 3 quarters. Management reported regulatory authorizations in Israel and Saudi Arabia in 2026-Q2 and clearance in UAE in 2026-Q1. These regulatory milestones support international commercial expansion, aligning with the company's distribution partnerships and growing scanner shipments globally.
“Securing regulatory authorization in Israel and Saudi Arabia.”
“Received FDA clearance and regulatory clearance in UAE.”
Continue product enhancements, clinical studies, and evidence generation to support adoption and reimbursement.
Stated as a priority in 2 of last 3 quarters. Management highlighted scientific evidence showing less than 1% variability in quantitative imaging biomarkers in 2026-Q2 and software enhancements plus clinical studies in 2026-Q1. These efforts support clinical validation and product advancement, consistent with the stated strategic focus.
“Generated scientific evidence demonstrating less than 1% variability in Speed of Sound measurements.”
“Launched software improvements and advanced clinical validation studies.”
Strengthen balance sheet via public offering and extend debt maturities to support growth investments.
Stated as a priority in 2 of last 3 quarters. Management completed a $10 million public offering in 2026-Q2 and extended the senior secured term loan maturity to March 31, 2029 in both 2026-Q1 and 2026-Q2. These actions strengthened the balance sheet and financial flexibility, supporting ongoing commercial and operational investments.
“Completed $10 million public offering and extended term loan maturity by two years.”
“Extended maturity date of senior secured term loan to March 31, 2029.”
Over the trailing year it converted 0.71x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
33 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.